Business
AIM Rule 26
AIM Rule 26.
About this update from Immupharma Plc
[{"type":"text","content":"\n Immupharma PLC\n20 August 2007\n\n\nFor Immediate Release 20 August 2007\n\n\n ImmuPharma PLC\n\n AIM Rule 26\n\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug \ndiscovery and development company, today announces that the information required \nby Rule 26 of the AIM Rules for Companies (February 2007) is available in the \ninvestor section of the Company's website \nat http://www.immupharma.com/AIM_Rule_26_Information.html.\n\n\n\nFor further information please contact:\n\nImmuPharma PLC:\nDimitri Dimitriou, Chief Executive Officer +44 20 7152 4080\nRichard Warr, Chairman +44 20 7152 4080\n \nBuchanan Communications + 44 20 7466 5000\nLisa Baderoon\nRebecca Skye Dietrich\n\nLandsbanki Securities (UK) Limited + 44 20 7426 9000\nJeff Keating\nThilo Hoffmann\n\n\nNotes to Editors:\n\nAbout ImmuPharma\n\n\nImmuPharma PLC is a drug discovery and development company headquartered in\nLondon, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has\nresearch operations in France (ImmuPharma (France) SA) and Switzerland\n(ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs,\nlargely based on peptide therapeutics, to treat serious medical conditions such\nas autoimmune diseases characterised by:\n\n\n* blockbuster potential in niche markets\n\n* low promotional costs in few specialised physicians and centres and\n\n* lower risk of drug development and lower development costs\n\n\nImmuPharma is a currently developing drug candidates for three different medical\nconditions, each of which would represent a significant breakthrough in its\nfield. The furthest advanced drug candidate targets Lupus, a disease for which\nthere is currently no cure or specific treatment. The other two address moderate\nto severe pain (such as that experienced by cancer sufferers and post-operative\npatients), and MRSA and similar severe hospital-acquired resistant infections.\n\nAll three have significant sales potential as well as low marketing costs and a\nrelatively low risk of development failure. One or more have the potential to be\nfast-tracked by the US Food and Drug Administration according to 'Guidance for\nIndustry: Fast Track Drug Development Programs - Designation, Development and\nApplication Review' issued July 2004 and could therefore obtain their market\nauthorization by 2010....